Evidence map›Paper›PMID 41621809›Full record

ArticleMolecular & cellular proteomics : MCP2026

High-Throughput Proteomic Profiling to Evaluate Differentiation Syndrome With Menin Inhibition.

Miriam B Garcia, Bofei Wang, Irtiza Sheikh, Georgina El Hajjar, David McCall, Cesar Nunez, Amber Gibson, Philip L Lorenzi, Ghayas C Issa, Branko Cuglievan and 1 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04065399 phase1 / phase2recruitingnot on this map

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

TypeinterventionalSponsorSyndax PharmaceuticalsRan2019 to 2027Enrolled447ConditionsAcute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute LeukemiaArmsrevumenib, cobicistat
NCT05360160 phase1 / phase2recruitingnot on this map

A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2022 to 2026Enrolled43ConditionsAcute Myeloid LeukemiaArmsSNDX-5613, Venetoclax, ASTX727
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Miriam B GarciaDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: mbgarcia@mdanderson.org.
Bofei WangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Irtiza SheikhDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Georgina El HajjarDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David McCallDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cesar NunezDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Amber GibsonDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Philip L LorenziDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ghayas C IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Branko CuglievanDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hussein A AbbasDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: habbas@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-throughput proteomic profiling provides a comprehensive analysis of systemic cancer effects and tumor microenvironment interactions. Characterizing soluble proteins driving inflammation in acute myeloid leukemia (AML) offers insight into inflammatory diseases like differentiation syndrome related to AML therapies like menin inhibitors. We present our application of nucleic acid-linked immuno-sandwich assay, a novel technology leveraging next-generation sequencing for high-throughput, ultrasensitive characterization of secreted inflammatory proteins in plasma or serum. Here, we report its use to identify dynamic soluble protein changes during treatment and at the time of suspected differentiation syndrome in pediatric AML patients treated with the menin inhibitor revumenib (NCT04065399 and NCT05360160).

Indexed as

Leukemia, Myeloid, AcuteProteomicsProto-Oncogene ProteinsCell DifferentiationHumansMEN1 protein, humanProto-Oncogene Proteinsacute myeloid leukemiadifferentiation syndromemenin inhibitorspediatricproteomicsrelapsed refractory AML

Identifiers

PMID41621809
PMCPMC12955094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.